5-APB Stats & Data
CC(N)Cc1ccc2ccoc2c1FQDAMYLMQQKPRX-UHFFFAOYSA-NReceptor Profile
Receptor Actions
History & Culture
1993–2000
The development of 5-APB emerged from research into benzofuran-based entactogens during the 1990s. Medicinal chemist David E. Nichols and colleagues at Purdue University conducted foundational work on benzofuran analogues, examining the role of the MDA dioxole ring structure in interacting with serotonergic neurons. This research was motivated in part by efforts to identify a potentially non-neurotoxic alternative to MDMA, which was being investigated as a possible adjunct to psychotherapy but was also raising concerns about neurotoxic effects. 5-APB and its positional isomer 6-APB were formally described in a patent by Karin Briner and colleagues at Eli Lilly and Company in 2000. These compounds were studied as serotonin 5-HT2C receptor agonists for potential therapeutic applications, though they were not developed further for medical use.
2010–present
Recreational use of 5-APB was not documented until 2010, when it emerged for sale on the global research chemical market. The compound became particularly prominent in the United Kingdom's "legal highs" market, where 5-APB and related benzofuran entactogens were sold under the brand name "Benzofury" and gained a following in the rave scene. This period of legal availability was relatively short-lived. Following recommendations from the Advisory Council on the Misuse of Drugs, 5-APB and related analogues were classified as controlled substances in the UK in 2014, effectively ending the legal sale of benzofuran entactogens in that country. Similar regulatory actions followed in other jurisdictions.
Effect Profile
Curated + 95 ReportsStrong visuals, auditory effects, and body load with moderate headspace
Strong empathy, euphoria, stimulation, and sensory enhancement
Strong stimulation, euphoria, focus, and anxiety/jitters
Duration Timeline
BluelightEmpirical Duration
Erowid ReportsCommunity Effects
TripSitTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Pattern inferred from user reports across benzofurans and MDMA-like agents. Acute tolerance develops within a session; effects are notably blunted by redosing late. Subjective tolerance partially subsides over 1–2 weeks, with baseline often reported after 3–5 weeks. Data quality: anecdotal/community-derived.
Cross-Tolerances
Demographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
Erowid + BluelightEffects aggregated from 95 experience reports (89 Erowid + 6 Bluelight)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 17
Adverse Effects 19
Dose-Response Correlation
How effect frequency changes across dose levels
View data table
| Effect | Heavy (n=38) |
|---|---|
| Euphoria | 84.2% |
| Visual Distortions | 68.4% |
| Music Enhancement | 68.4% |
| Stimulation | 68.4% |
| Empathy | 65.8% |
| Color Enhancement | 47.4% |
| Jaw Clenching | 47.4% |
| Tactile Enhancement | 42.1% |
| Sweating | 36.8% |
| Nausea | 34.2% |
| Sedation | 34.2% |
| Anxiety | 34.2% |
| Confusion | 31.6% |
| Pupil Dilation | 26.3% |
| Auditory Effects | 26.3% |
Dose–Effect Mapping
Experience ReportsHow reported effects shift across dose tiers, based on 89 experience reports.
Limited tier coverage — most reports fall within the Heavy range. Effects at other dose levels may not be represented.
| Effect | Heavy (n=38) | |
|---|---|---|
| euphoria | ||
| visual distortions | ||
| music enhancement | ||
| stimulation | ||
| empathy | ||
| color enhancement | ||
| jaw clenching | ||
| tactile enhancement | ||
| sweating | ||
| nausea | ||
| sedation | ||
| anxiety | ||
| confusion | ||
| pupil dilation | ||
| auditory effects | ||
| body high | ||
| focus enhancement | ||
| open-eye visuals | ||
| headache | ||
| creativity enhancement |
Showing top 20 of 30 effects
Dosage Distribution
Dose distribution from experience reports
Real-World Dose Distribution
62K DosesFrom 133 individual dose entries
Oral (n=98)
Insufflated (n=17)
Common Combinations
Most co-occurring substances in experience reports
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Redose Patterns
Redosing behavior across 71 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Brazil | Illegal | Listed on Portaria SVS/MS nº 344. Possession, production, and sale are prohibited under Brazilian drug control legislation. |
| France | Narcotic | Classified as a narcotic substance since May 9, 2018, alongside other benzofuran-derived compounds. |
| Germany | Anlage II BtMG | Controlled under Anlage II of the Betäubungsmittelgesetz (Narcotics Act, Schedule II) since July 17, 2013. Manufacturing, possession, import, export, purchase, sale, procurement, or dispensing without a license is illegal. |
| Japan | Controlled substance | Designated as a controlled substance effective September 16, 2015. |
| Netherlands | Legal (under review) | Currently unscheduled, though it belongs to a substance group that may be prohibited under recently passed New Psychoactive Substances (NPS) legislation. |
| Switzerland | Controlled (Verzeichnis E) | Specifically named as a controlled substance under Verzeichnis E of Swiss drug control legislation. |
| United Kingdom | Class B | Initially classified as a Temporary Class Drug on June 10, 2013. Made a permanent Class B, Schedule 1 substance on June 10, 2014 alongside all other benzofuran entactogens and structurally related compounds. |
| United States | Unscheduled (Analogue Act applies) | Not specifically scheduled at the federal level. However, due to structural similarity to MDA, it may be prosecuted under the Federal Analogue Act if sold or possessed with intent for human consumption. |
Harm Reduction
drugs.wikiProduct mislabeling and salt-form variability are common in the benzofuran market; material sold as “Benzo Fury” may contain 5‑APB, 6‑APB, mixtures, or unrelated actives—use multi-reagent testing and consider sending a small sample to a drug-checking service before dosing. The come-up can be slow (often 60–120 min) with a wave-like rise; premature redosing in the first 2–3 hours markedly increases risk of over-intoxication, nausea, and cardiovascular strain. 5‑APB is commonly encountered as the HCl or succinate salt; by weight, HCl contains more active base than succinate—doses should be reduced if the material is HCl or unusually pure. Reagent behavior can resemble MDMA on some tests (e.g., Marquis/Mecke dark reactions), so use a panel (e.g., Froehde, Simon’s) rather than a single reagent and avoid assuming MDMA results confirm MDMA. As a serotonergic entactogen with stimulant properties, 5‑APB should not be combined with MAOIs, DXM, tramadol, triptans, or serotonergic supplements (5‑HTP) due to serotonin toxicity risk; combining with other stimulants amplifies hypertension, hyperthermia, and arrhythmia risk. Benzofurans show concerning 5‑HT2B activity in vitro discussions; although clinical data are limited, frequent use may pose a theoretical valvulopathy risk—pace use (e.g., several weeks between sessions) and avoid if you have heart disease. Manage environment and temperature: take breaks from heat, sip water regularly, and include electrolytes on long sessions; avoid heavy alcohol (dehydration, masking warning signs). Common adverse effects include jaw clenching, nausea/vomiting on come-up, headaches during/after, insomnia, and transient anxiety—dose control, cool ambient temperature, and avoiding redose can mitigate these. Insufflation is irritating and may increase intensity but reduce duration; oral administration is generally preferred for smoother effects. Cross-tolerance with MDMA/MDA and similar entactogens is reported; spacing uses reduces “muted” effects and post-acute low mood. Because benzo fury-era products were often adulterated, be cautious with pressed pellets or unusually colored powders, and titrate with an accurate milligram scale after reagent testing.
References
Cited References
- Baumann et al. 2018 - Pharmacology of 5-APB and 6-APB (PMC)
- Briner et al. 2006 - Aminoalkylbenzofurans as 5-HT2C Agonists Patent
- Dawson et al. 2014 - Effects of Benzofury on Dopamine Transporter
- DrugWise: Benzofury Factsheet
- Iversen et al. 2013 - Neurochemical Profiles of Novel Psychoactive Substances
- IsomerDesign PIHKAL: 5-APB
- Monte et al. 1993 - Synthesis and Pharmacology of Benzofuran Analogues
- Rickli et al. 2015 - Pharmacological Profile of Novel Psychoactive Benzofurans
- DrugWise: Benzo Fury
Drugs.wiki References
- IsomerDesign PIHKAL: 5-APB (general background)
- Drugs-Forum Wiki: 5-APB (doses, onset/plateau length, reagent behavior)
- Bluelight: List of Dangerous & Potentially Unsafe Combinations (serotonergic/stimulant interactions)
- Bluelight: 5‑APB & 6‑APB can mimic MDMA on reagents; use Froehde/Simon's and multi-reagent panels
- Bluelight (discussion): Salt form commonality and HCl vs succinate considerations for benzofurans
- Reddit (community harm-reduction): Succinate vs HCl potency by weight math for 6‑APB (analogous principle for 5‑APB)
- Bluelight: The 5‑HT2B receptor, valvulopathy and safety discussions (risk rationale to pace use)
- Bluelight: Big & Dandy/APB threads (reports on delayed come-up, redose effects, ROA differences)